UiPath (NYSE:PATH) PT Raised to $25.00 at Wells Fargo & Company

UiPath (NYSE:PATH) had its price objective boosted by Wells Fargo & Company from $24.00 to $25.00 in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the healthcare company’s stock.

A number of other equities research analysts have also recently commented on the company. Mizuho lifted their target price on UiPath from $22.00 to $25.00 and gave the stock a neutral rating in a research note on Thursday. DA Davidson lifted their price objective on UiPath from $20.00 to $24.00 and gave the stock a neutral rating in a report on Thursday. Needham & Company LLC lifted their target price on UiPath from $25.00 to $30.00 and gave the company a buy rating in a report on Thursday. BMO Capital Markets boosted their price objective on UiPath from $24.00 to $28.00 and gave the stock a market perform rating in a report on Thursday. Finally, Evercore ISI boosted their target price on UiPath from $24.00 to $27.00 and gave the stock an in-line rating in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $27.13.

UiPath Stock Performance

Shares of PATH stock traded up $0.32 during trading hours on Thursday, hitting $23.07. 9,842,354 shares of the company were exchanged, compared to its average volume of 10,074,664. The company has a 50 day simple moving average of $23.52 and a two-hundred day simple moving average of $20.70. UiPath has a fifty-two week low of $12.38 and a fifty-two week high of $27.87. The firm has a market cap of $13.06 billion, a P/E ratio of -135.46 and a beta of 0.97.

Insider Activity

In related news, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the completion of the transaction, the chief financial officer now directly owns 103,505 shares in the company, valued at $2,325,757.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other UiPath news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the transaction, the director now owns 429,418 shares in the company, valued at approximately $9,928,144.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ashim Gupta sold 16,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the sale, the chief financial officer now directly owns 103,505 shares in the company, valued at approximately $2,325,757.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 411,000 shares of company stock valued at $9,418,670. 31.03% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Royal London Asset Management Ltd. increased its holdings in shares of UiPath by 5.9% during the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock worth $2,388,000 after buying an additional 7,742 shares during the last quarter. Barclays PLC grew its stake in shares of UiPath by 55.2% during the second quarter. Barclays PLC now owns 968,036 shares of the healthcare company’s stock valued at $16,039,000 after acquiring an additional 344,499 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in shares of UiPath during the third quarter valued at about $203,000. Invesco Ltd. lifted its position in shares of UiPath by 2.8% during the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock worth $6,830,000 after purchasing an additional 10,863 shares during the last quarter. Finally, Symmetry Partners LLC bought a new position in shares of UiPath during the fourth quarter worth about $205,000. Hedge funds and other institutional investors own 59.04% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.